Product image of Lacosamide Treatment Initiation Pack (In Adolescent And Children Weighing 50 Kg Or More And Adults O (Lacosamide) supplied by GNH India

Lacosamide Treatment Initiation Pack (In Adolescent And Children Weighing 50 Kg Or More And Adults O

Active Ingredient:
Lacosamide
Origin:
EU

Lacosamide Treatment Initiation Pack (In Adolescent And Children Weighing 50 Kg Or More And Adults O (Lacosamide)

Lacosamide, the active ingredient in Lacosamide Treatment Initiation Pack, is an antiepileptic presented as an oral formulation for oral use. It is indicated for the adjunctive treatment of partial‑onset seizures in adolescents, children weighing 50 kg or more, and adults.

GNH India supplies Lacosamide Treatment Initiation Pack as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Clients benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical support.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lacosamide is an antiepileptic drug used to control seizure activity in the focal seizure pathway.
  • Partial‑onset (focal) seizures: reduces seizure frequency as adjunctive therapy.
  • Adjunctive therapy for epilepsy: enhances overall seizure control when added to existing antiepileptic regimens.
  • Adolescents and children weighing ≥50 kg: provides a starting regimen for seizure management in patients aged 12 years and older.

How It Works

  • Lacosamide selectively enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing the inactive state of these channels, it diminishes repetitive neuronal firing and reduces hyper‑excitability that underlies seizure generation. The drug does not significantly affect fast sodium channel kinetics, allowing targeted modulation of epileptogenic pathways. This mechanism contributes to its efficacy across a broad spectrum of focal seizure types and supports its use as an adjunct in diverse therapeutic regimens.

Side Effects

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Dizziness
  • Nausea
  • Headache
  • Fatigue
  • Blurred vision
  • Diplopia

Serious or Rare Side Effects

  • Cardiac conduction abnormalities (e.g., PR interval prolongation)
  • Suicidal thoughts or behavior
  • Severe skin reactions such as Stevens‑Johnson syndrome
  • Hypersensitivity reactions including anaphylaxis
  • Hepatic enzyme elevations
  • Blood dyscrasias (e.g., neutropenia, thrombocytopenia)

Precautions & Warnings

  • When prescribing lacosamide, clinicians should consider several precautionary measures to ensure patient safety.
  • Pregnancy: Category C; weigh potential benefits against risks and monitor fetal development.
  • Renal impairment: assess kidney function and adjust dose as needed.
  • Hepatic impairment: use with caution; monitor liver enzymes.
  • Cardiac conduction: obtain baseline ECG and monitor for PR interval changes.
  • Concomitant antiepileptic drugs: evaluate for possible additive CNS effects.
  • Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels.
  • Drugs that prolong PR interval (e.g., class IA antiarrhythmics): increase risk of cardiac conduction delays.
  • Other sodium channel blockers (e.g., lamotrigine): may enhance central nervous system adverse effects.

Moderate Interactions (Monitor Closely)

  • Concurrent antiepileptic drugs: may require dose adjustments based on therapeutic response.
  • Hormonal contraceptives: lacosamide may reduce contraceptive effectiveness; consider alternative methods.
  • Alcohol: combined use can increase dizziness and sedation.

Frequently Asked Questions

Lacosamide Treatment Initiation Pack is used as an adjunctive therapy to control partial‑onset (focal) seizures in adolescents, children weighing 50 kg or more, and adults. It helps reduce seizure frequency when added to existing antiepileptic regimens.

Lacosamide works by selectively enhancing the slow inactivation of voltage‑gated sodium channels in neurons. This stabilises the inactive channel state, limiting repetitive firing and neuronal hyper‑excitability that contribute to seizure generation.

The dose of lacosamide is individualized by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here; the prescriber sets the appropriate dosage.

Lacosamide is classified as Pregnancy Category C, indicating that risk cannot be ruled out. It should only be used if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding, so caution is advised.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with many traditional antiepileptics, lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—offers a different safety profile and may be better tolerated in some patients. It is often used when other agents are insufficient or cause intolerable side effects.

Lacosamide Treatment Initiation Pack should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. No refrigeration is required for this oral formulation.

Lacosamide is administered orally, typically as tablets or oral solution, and taken with or without food as directed by the prescriber. The exact dosing schedule is determined by the treating physician.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, suicidal thoughts or behaviours, severe skin reactions like Stevens‑Johnson syndrome, hypersensitivity reactions, and significant hepatic enzyme elevations. Patients should be monitored for these events.

Lacosamide should be avoided in patients with known hypersensitivity to the drug, those with significant cardiac conduction disorders without appropriate monitoring, and individuals in whom the risk outweighs the benefit as assessed by a qualified healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lacosamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT